TIMP1 and diffuse large B-cell lymphoma: Of the 89 DLBCL patients with low or low-intermediate IPI scores in the discovery cohort treated with R-CHOP/R-CHOP–like therapy, 29.2% (26/89) of the patients had high TIMP-1 expression levels (above the third quartile) while 70.8% (63/89) had low TIMP-1 expression levels (below the third quartile).